(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of -2.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 129.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.54%.
Maravai Lifesciences Holdings's revenue in 2025 is $241,856,000.On average, 4 Wall Street analysts forecast MRVI's revenue for 2025 to be $49,966,234,512, with the lowest MRVI revenue forecast at $47,986,766,086, and the highest MRVI revenue forecast at $52,205,200,985. On average, 4 Wall Street analysts forecast MRVI's revenue for 2026 to be $56,010,323,488, with the lowest MRVI revenue forecast at $53,631,294,280, and the highest MRVI revenue forecast at $59,633,619,096.
In 2027, MRVI is forecast to generate $73,965,347,394 in revenue, with the lowest revenue forecast at $73,965,347,394 and the highest revenue forecast at $73,965,347,394.